Fresenius Medical Care Sees US Plans for Kidney Disease as Positive
Browser Upgrade Recommended: Our website has detected that you are using a version of Internet Explorer that will prevent you from accessing certain features on FMCNA.com. We strongly recommend that you use a different browser to optimize your viewing experience. Supported browsers include Chrome, Edge, Firefox, and Safari.
Regenerative medicine is an emerging interdisciplinary field with dynamic potential clinical applications focused on the repair, replacement, or regeneration of dysfunctional cells, tissues, or organs from a range of problems, including congenital defects, disease, trauma, or aging. Regenerative medicine encompasses a combination of approaches, moving beyond traditional transplantation or replacement therapies. These methods include the use of soluble molecules, gene therapy, stem cell transplantation, tissue engineering, and reprogramming of cell and tissue types.1,2
Regenerative medicine holds the promise of regenerating damaged tissues and organs by stimulating previously irreparable organs to heal themselves. It also enables scientists to grow tissues and organs in the laboratory and safely implant them when a patient’s body cannot heal itself—allowing for “off the shelf” rationally designed tissues or organs. Taken to its limits, regenerative medicine has the potential to bridge the gap between the relatively small number of organs available for donation and the much larger number of patients in need of lifesaving organ transplantation.3
Regenerative medicine research has evolved into four broad areas of concentration:
Regenerative medicine has opened new avenues for curing patients with difficult-to-treat diseases and physically impaired tissues. Despite many successes, this field is still unfamiliar to many scientists and clinicians. This limitation is unfortunate, as tissue engineering and regenerative medicine could overcome the seemingly unsolvable problems faced by current medical treatments. Cell therapy and tissue engineering have the potential to revolutionize patient care. The key is transforming current scientific discoveries into novel and viable therapies.5
Patients with ESRD stand to benefit, potentially, from advances in regenerative medicine. Of course, the possibility of bioengineered replacement kidneys looms just beyond the horizon as a veritable disease-changing pot of gold. However, more tangible possibilities also exist, including the availability of bioengineered hemodialysis grafts that address many of the pitfalls in current hemodialysis access care (Figure 1).
Patients undergoing hemodialysis require reliably patent, infection-free vascular accesses in order to receive life-sustaining dialysis. During the last 50 years that hemodialysis has been in use, the arteriovenous fistula (AVF) has emerged as the access option of choice for these patients. Yet, as the most recent available data reveals, unacceptably high numbers of these accesses never mature to the point of being useful.6 Furthermore, even
Bioengineered vessels have emerged as cost-effective, reliable, and safe alternatives to
Figure 1 | Bioengineered human acellular vessels: an innovation in haemodialysis. Development of the human acellular vessel is an example of combining technological and biological advances to address an unmet clinical need. If shown to be efficacious, this new technique could have important ancillary benefits such as enabling precision medicine approached and increasing health-care value for patients on haemodialysis as well as potential uses in other vascular and non-vascular applications.
Source: P. Roy-Chaudhury, Dialysis: bioengineered vessels for dialysis access: soon to be a reality?Nat Rev Nephrol 2016;12(9):516-17.
The imaging appearance of humacyte grafts in the limited available experience to date provides no characteristic features to suggest the access is a humacyte graft. For example, while on ultrasound, humacyte grafts can be distinguished from ePTFE grafts by the absence of hyperechoic (bright white) lines outlining the graft (Figures 2 and 3), these features are also seen in fistulas. And, the fluoroscopic appearance of humacyte grafts is identical to that of ePTFE grafts (Figure 4). Therefore, clinical history is critical since angioplasty balloon sizes greater than 6mm and mechanical thrombectomy devices (all common tools for the interventionalist) are contraindicated in humacyte grafts that require intervention.
If further trials continue to show the benefits reported in this phase II study, bioengineered vessels such as these could represent a needed value proposition in the costly ESRD world and would begin to fulfill the promise of regenerative medicine. One can imagine a day in the not-too-distant future when “off the shelf” bioengineered acellular coronary artery and other bypass grafts will be used to treat other pervasive vascular diseases.
Figure 2 | Angled longitudinal ultrasound image of a needle being used to access a conventional ePTFE graft. Note the hyperechoic (bright) borders outlining the graft. The bright dot towards the top is the tip of the needle being used to access the graft.
Figure 3 | Transverse ultrasound image of a needle being used to access a humacyte graft. Note the lack of a defined border visible by ultrasound; this appearance is similar to that of a fistula. The bright line coming from superior aspect is the needle.
Figure 4 | Fluoroscopic image from a fistulagram showing a humacyte graft with puncture-site pseudoaneurysms. The access point is just below the lowest pseudoaneurysm. The fluoroscopic appearance of a humacyte graft is indistinguishable from that of a conventional graft.
Murat Sor, MD
Chief Medical Officer, Azura Vascular Care
A graduate of the University of Pennsylvania, Murat Sor is certified by the American Board of Radiology, with subspecialty certification in interventional radiology. He is an assistant professor at Georgetown University Hospital’s Interventional Radiology Fellowship program and an adjunct instructor at the George Washington University School of Medicine.
Warren S. Krackov, MD, MA, MS
Medical Director, Vascular Interventions of Tampa
Warren S. Krackov is an interventional radiologist who specializes in dialysis access management and was a pioneer in performing transradial uterine fibroid embolization in the outpatient setting. He performs a full range of dialysis access procedures, including treatments for critical maintenance and management for a dialysis patient’s accesses. He serves on the Medical Advisory Board of Azura Vascular Care.
Catherina Madormo, RN, BSN
Clinical Research Manager, Azura Vascular Care
Catherina (Kitty) Madormo supports the work of the chief medical officer, the Medical Advisory Board, and Azura physicians involved with the network’s clinical research activities. She serves as the point of contact between Azura and other FMCNA research entities and works with Azura’s marketing team as a clinical subject matter resource. She earned her bachelor’s degree in nursing from Seton Hall University and has been involved in the care and treatment of nephrology patients throughout her career.
Regenerative Medicine: Immediate Reality and Long-Term Promise
by Murat Sor, MD, Warren S. Krackov, MD, MA, MS & Catherina Madormo, RN, BSN